USP Draft Medicare Formulary Update Adds Nine Classes, Targeted Cancer Drugs
Executive Summary
Released Oct. 1, the draft update to the USP Medicare Model Formulary Guidelines includes several new classes formed to accommodate novel therapies approved in the last three years, including targeted cancer drugs.
You may also be interested in...
USP Formulary Guidelines Back In Spotlight With Essential Health Benefits Proposal
HHS proposes to use USP’s drug classification system, created as a guideline for Medicare Part D formularies, to facilitate “review, analysis and comparison” of the breadth of drug coverage offered by individual and small group private insurance plans beginning in 2014.
Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs
The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026.
Biosimilar Substitution In Medicare Part D Formularies Mid-Year Established In Final Rule
Policy may be helpful in promoting acceptance of follow-ons in Medicare but is not expected to result in near-term savings to the program.